ADSL and digestive system infectious disorder: This unique approach leverages the intrinsic antimicrobial properties of AMPs, enabling targeted delivery and protection of AMPs in addition to controlled and sustained release in the GIT.[20] The effectiveness of these nanocarriers lies in the ability of nanomaterials to increase the stability, bioavailability, and selectivity of AMPs, thereby increasing their efficacy against intestinal pathogens.[9, 21] This combination promises to combat intestinal infections more effectively, mitigating potential side effects and minimizing the development of bacterial resistance.